Sanofi/Regeneron win 1st US PCSK9 OK with Praluent
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron Pharmaceuticals on 24 July pulled off the first US approval of a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor – gaining the FDA's nod for Praluent (alirocumab).